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Forssman glycolipid (FG), the product of Forssman synthetase (FS), is widely expressed among nonprimate
mammalian species. Here, we describe a molecular and genetic relationship between FG expression and Shiga
toxin (Stx) susceptibility. We have isolated the FS cDNA from human, canine, and murine cells. Whereas the
murine and canine FS genes express a functional enzyme, the human FS cDNA was found to express a protein
that lacks FS activity, despite a high degree of sequence identity with the enzymatically active murine and
canine FS genes. In order to examine the relationship between FG expression and Stx susceptibility, Vero cells
were transfected with the three FS orthologues or a vector control. Complementation with the human FS cDNA
had no effect on Stx susceptibility, whereas stable expression of the canine and murine FS resulted in markedly
decreased susceptibility to toxin. Among individual cells, an inverse correlation between FG expression and Stx
binding was demonstrated. Moreover, only strongly FG-reactive cells were capable of growing in the presence
of Stx. These cells were found to have high levels of FG expression and a correspondingly diminished GbO3
content. We conclude that expression of a functionally active FS modifies Stx receptor glycolipids to FG and
results in markedly decreased susceptibility to toxin. We speculate that inactivation of the FS gene during
primate evolution may account, at least in part, for the marked susceptibility of human cells to Stx.
Shiga toxins (Stx) are highly conserved exotoxins released by
serotypes of Escherichia coli (predominantly O157:H7), Shi-
gella, and other pathogenic gram-negative bacteria (23, 28).
Human exposure to Stx typically follows ingestion of contam-
inated foods and results in severe hemorrhagic colitis. In rare
cases, systemic toxemia results in damage to other organs, such
as the kidneys, brain, and heart. The resulting disease complex,
known as hemolytic uremic syndrome (HUS), occurs in up to
10% of children infected with E. coli O157:H7 and is the most
common cause of acute renal failure in childhood (26, 32).
Stx follows a complex intracellular pathway in order to kill
susceptible cells. After binding to cell surface glycolipids, the
toxin is internalized and trafficked in retrograde fashion to the
Golgi and endoplasmic reticulum. From the endoplasmic re-
ticulum lumen the toxin must gain access to the cytoplasm,
where it enzymatically inactivates rRNA, inhibiting protein
synthesis, and ultimately leads to cell death. In cultured cells
and in whole tissues, susceptibility to Stx is most strongly cor-
related with the presence of its predominant receptor, the
glycolipid globotriaosylceramide (GbO3) (25, 33). The related
glycolipid globoside (GbO4, which differs from GbO3 only by
an additional N-acetylgalactosamine residue) also binds some
variants of Stx, and its presence confers cells with susceptibility
to those variants, particularly the pig edema toxin (Stx2e).
Thus, presence of globoseries glycolipid GbO3, and to a lesser
extent GbO4, is the most important feature determining wheth-
er a cell is susceptible to Stx. These observations have direct
clinical relevance in that the tissues damaged most in HUS are
those with high levels of GbO3 expression. Moreover, children
are more susceptible to HUS than adults at least partially due
to their higher levels of kidney GbO3 expression (19, 24).
All mammalian species produce glycolipid GbO3, yet many
display markedly less susceptibility to toxin when compared to
humans. For example, cattle and sheep are frequently in con-
tact with toxigenic bacteria without consequence. Indeed, be-
tween 5 and 80% of animals in individual herds are colonized
with Stx-producing E. coli, yet these animals rarely manifest
symptoms (3, 4, 17). A corresponding differential in Stx sus-
ceptibility exists in vitro, where cell lines derived from human
and primate sources are often exquisitely sensitive to Stx while
cells from other animal species are generally much less sus-
ceptible (25, 35).
We examine here the possibility that Forssman synthetase
(FS) expression has an impact on Stx susceptibility. FS modi-
fies receptor-active glycolipids GbO3 and GbO4 to Forssman
glycolipid (FG), which does not bind toxin. Whereas many
mammals widely express a functional FS enzyme, humans are
unable to produce this glycolipid. We have recently demon-
strated that mutations in the catalytic domain of the human FS
protein render the molecule functionally inactive, accounting
for the lack of FG synthesis by human cells (36). Here, we
describe cloning of the murine FS cDNA and demonstrate that
complementation of primate cells with the canine or murine
FS results in markedly reduced susceptibility to Stx. An inverse
correlation was seen between FG expression and binding of Stx
to individual cells. We demonstrate that exposure of FS-ex-
pressing cells to Stx results in selection and maintenance of
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high-level FG expression and markedly reduces cellular con-
tent of Stx receptor glycolipids. These results demonstrate that
variability in glycolipid expression among species may have a
profound effect on susceptibility to an infectious agent and
provide insight into the molecular evolution of glycosyltrans-
ferase gene expression.
MATERIALS AND METHODS
Cell lines and antibodies. Cell lines were maintained in Dulbecco’s modified
Eagle medium (DMEM) containing 10% fetal bovine serum (Gibco BRL, Grand
Island, N.Y.). Vero cells (African green monkey adult kidney cells; ATCC
CCL-81; American Type Culture Collection, Bethesda, Md.) were transfected
with plasmid pFS-35 (canine FS) (9), pFS-36 (transfected and neomycin-selected
wild-type control; created by deleting a 400-bp ApaI fragment from plasmid
pFS-35 within the predicted catalytic domain), pHFS (human FS) (36), or pMFS
(murine FS) using Lipofectamine reagent (Gibco BRL). Approximately 5  105
Vero cells were transfected with a suspension containing 3 g of each plasmid
DNA and 50 l of Lipofectamine. Forty-eight hours later, neomycin (Gibco
BRL) was added to the medium to a concentration of 800 g/ml, and neomycin-
resistant clones were allowed to proliferate. After 10 days, cells transfected with
the canine or murine FS were subjected to fluorescence-activated cell sorting
(FACS) with monoclonal anti-Forssman antibody (M1/22.25.8). The 5% of cells
reacting most strongly with anti-Forssman antibody were selected and further
expanded in the presence of neomycin. After passage in the presence of neomy-
cin for 8 weeks, approximately 40% of FS-transfected cells continued to express
FG as demonstrated by FACS (see Fig. 3, below). Despite FACS selection for
single clones containing FG-positive cells, a large percentage of selected cells
became FG negative within several passages. Cells transfected with pFS-36
(wild-type cells) or the human FS were expanded directly in the presence of
neomycin.
Cloning of the murine FS genomic locus and cDNA. An internal fragment of
the murine FS gene was amplified from mouse genomic DNA with degenerate
primers FS-26 (5-TTCRTCCAGYMCTTCCTGGAGTC-3, where R  A/G,
Y  C/T, M  A/C) and FS-28 (5-CAGAGGTACTCRGGGGACAGC3),
based on conserved regions within the canine (9) and human (36) FS sequences
and known to be within a single exon of the human FS gene. A PCR product of
530 bp was obtained, subcloned, and sequenced. The insert was radiolabeled and
used as a probe to screen an SvJ mouse genomic library cloned into -Fix
(Stratagene). One million plaques were screened, revealing three hybridizing
clones. These were further purified until two individual strongly hybridizing
plaques were isolated. The insert in one (-2-2-3) was found to contain the entire
coding region, spanning seven exons, over approximately 9 kb. In order to
identify the start codon and transcriptional start site, 5 rapid amplification of
cDNA ends (5-RACE) was performed. Primers MFS-7 (5-CCCCACCATAA
TAGAAGTCCC-3) and AP-1 (Clontech) were used in the first-round PCR
using primer-anchored mouse lung cDNA as template (Clontech). A second
round of PCR utilizing nested primers MFS-8 (5-CCCCACGGCAAACACSG
TGACSCC-3, where S  G/C) and AP-2 (Clontech) yielded a single product of
approximately 535 bp containing approximately 90 bp of 5-untranslated message
and 347 bp of coding region. Using sequence information derived from the
5-RACE product and the 3 end of the genomic clone, primers MFS-44
(5-GCCGCCGCCATGACCCGCCCAAGACTGGCCCAGGGCC) and
MFS-43 (5-ATGTTAGGTCCTCAGCCAGTTGGCATTCTTTTTCACTGG-
3), which overlap the start and stop codons, respectively, were used to amplify
the full-length mouse FS cDNA from a murine lung cDNA library. The 1.1-kb
product was ligated into vector pCR3.1Topo/His/V5 to create plasmid pMFS.
The insert was sequenced and compared to the canine and human FS genes as
well as the mouse EST database. Transfection of Vero cells with the cloned
murine FS cDNA resulted in strong reactivity with anti-FG antibody, indicating
that the cloned cDNA was functional (data not shown).
Holotoxin and Stx B-subunit (StxB) purification. Semipurified Stx1 was pre-
pared from E. coli harboring the genes encoding Shigella dysenteriae Stx1 on
plasmid pNAS13 (generously provided by Alison O’Brien), which contains the
operon on a 3.4-kb NcoI fragment from pNAS4 (30). Two-liter cultures of these
bacteria were grown overnight at 37°C. Periplasmic extraction was performed by
osmotic shock (22). The extract was concentrated to 10 ml and then subjected to
anion-exchange chromatography on a Q-Sepharose column using a gradient
from 20 mM Tris (pH 7.5) to 20 mM Tris (pH 7.0)–1 M NaCl. A peak containing
Stx1 eluted at 0.15 mS/cm. These fractions were pooled and further purified by
gel filtration using a Superdex 75 HR 10/30 column equilibrated with phosphate-
buffered saline (PBS). Stx1 eluted at approximately 6 ml, as determined by
reactivity with anti-StxB on dot immunoblotting and cytotoxicity assays. For
cytotoxicity assays, highly purified Stx was utilized (List Laboratories).
The gene encoding StxB was amplified by PCR from plasmid pNAS13 and
cloned into plasmid pT7-7 to create pT7B5-1. Purification of recombinant StxB
from periplasmic extract was performed from a 1-liter culture by growing in
Luria-Bertani broth to an optical density at 600 nm of 0.6, after which isopro-
pylthiogalactoside was added to 1 mM and cultures were incubated a further 2 h
at 37°C. Periplasmic extraction was performed by osmotic shock (22). The extract
was concentrated to 15 ml and then subjected to anion-exchange chromatogra-
phy on a Q-Sepharose column using a gradient from 20 mM Tris (pH 7.5) to 20
mM Tris (pH 7.0)–1 M NaCl. A single peak containing StxB eluted at 0.44
mS/cm. This fraction was further purified by gel filtration using a Superdex 75
HR 10/30 column equilibrated with appropriate buffer (PBS for radiolabeling;
0.1 M carbonate [pH 9.5] for AlexaFluor 488 conjugation). Pentameric StxB
eluted at approximately 14 ml. StxB was radiolabeled with 125I using Iodogen
beads (Pierce) to a specific activity of 2  105 cpm/pmol. AlexaFluor 488 con-
jugation of StxB was performed with reagents from Molecular Probes following
the manufacturer’s instructions.
Cytotoxicity assays. Equal numbers of wild-type or FS-transfected cells were
suspended in 400 l of replete medium, and 2.5  104 cells were aliquoted into
24-well dishes. The following day, increasing dilutions of Stx1 (15,000 to 1.5
ng/ml; List Laboratories) were added. Cells were then exposed to toxin dilutions
in complete medium for 48 h in order to maximize toxin effect. Similar results
were seen with a 4-h incubation in the presence of toxin, though the degree of
protein synthesis inhibition was less profound among all cell types (data not
shown). Cell monolayers were then washed two times with PBS and then incu-
bated in Cys-Met-free medium containing [35S]Cys-Met (ICN Biomedicals, Inc.,
Costa Mesa, Calif.) at 10 Ci/ml. The cells were incubated for 30 min at 37°C,
washed six times in PBS, and lysed by the addition of 500 l of 0.2% sodium
dodecyl sulfate in 50 mM Tris (pH 7.5). Trichloroacetic acid (TCA) was added
to 10%, and the samples were incubated on ice for 30 min. After a 10-min
centrifugation at 14,000  g, the supernatant was removed and the pellet was
washed in 10% TCA and then transferred to a scintillation tube. Incorporation
of [35S]Cys-Met was determined by scintillation counting of precipitated lysates.
Confocal immunofluorescence. Wild-type Vero cells or those transfected with
the human, murine, or canine FS cDNA were harvested, and 104 cells were
seeded in 500 l of DMEM containing 10% fetal calf serum in microchamber
slides. After allowing cells to attach for 6 h at 37°C, AlexaFluor 488-labeled StxB
(prepared as above) or AlexaFluor 488-labeled cholera toxin B-subunit (Molec-
ular Probes) was added at 1 g/ml. Monoclonal anti-Forssman antibody (M1/
22.25.8) was added to all wells at 1:200 dilution, and the cells were allowed to
incubate for 30 min at 4°C. Cells were washed once with 1 ml of PBS and then
resuspended in 500 l of DMEM containing 10% fetal calf serum and Alexa-
Fluor 568-conjugated anti-rat immunoglobulin M (IgM; Molecular Probes) at
1:200 and allowed to incubate at 4°C for 60 min. Cells were washed twice in cold
DMEM plus 10% fetal calf serum, then once in cold PBS, and then fixed in 50
l of PBS containing 2% paraformaldehyde (Fisher Scientific, Fair Lawn, N.J.).
The slides were washed several times in blocking buffer and then PBS, mounted
with Aqua PolyMount (Polysciences, Warrington, Pa.), and visualized by epiflu-
oresence confocal microscopy (Bio-Rad). Image processing was performed with
the LaserSharp 1024 software package.
FACS analysis. The indicated cells were harvested by trypsinization and then
labeled with antibody M1/22.25 (anti-Forssman), and either AlexaFluor 488-
labeled StxB (prepared as described above) or AlexaFluor 488-labeled cholera
toxin B-subunit (Molecular Probes) was added at 1 g/ml. After rinsing, Alex-
aFluor 568-conjugated anti-rat IgM was added at a 1:100 dilution in labeling
buffer and incubated for 30 min at 4°C. After washing three times with labeling
buffer, cells were resuspended in 1% paraformaldehyde in PBS and subjected to
FACS analysis.
Stx binding assay. Wild-type cells or those stably transfected with the canine
FS and passaged in the presence of Stx1 (1 g of semipurified toxin/ml) were
resuspended in 200 l of complete medium containing various amounts
of StxB labeled to a specific activity of 2  105 cpm/pmol with 125I. After 1 h of
incubation at 4°C, cells were centrifuged through 800 l of ice-cold fetal calf
serum at 10,000  g for 1 min, the supernatant was removed, and cell-associated
toxin was quantitated in a gamma counter. In parallel experiments, cells were
preincubated in excess unlabeled StxB (2 mM) for 30 min, followed by the
addition of 125I-labeled toxin at various concentrations to determine the amount
of nonspecific binding at each concentration of labeled toxin.
TLC immuno-overlays and [125I]Stx overlays. Crude lipid extracts were pre-
pared from 5  105 wild-type Vero cells or those transfected with the canine FS
and passaged in the presence of Stx. Cells were harvested by trypsinization,
pelleted by centrifugation, and then resuspended in a volume of methanol equal
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to the cell pellet. One volume of chloroform was added, and after vortexing
vigorously methanol was added dropwise until organic and aqueous layers re-
solved into a single phase (approximately one additional volume of methanol).
Cellular debris was removed by centrifugation, and the organic supernatant was
evaporated under a stream of nitrogen. The lipid residue was resuspended in 60
l of chloroform-methanol-water (65:35:8), and 20 l of each was spotted onto
a thin-layer chromatography (TLC) plate. After developing in chloroform-meth-
anol-water (65:35:8), the plate was air dried and blocked with 5% bovine serum
albumin (BSA) in PBS. Forssman antigen was detected by TLC immunolabelling
and enhanced chemiluminescence (ECL) as previously described (8). Briefly, the
plate was overlaid with antibody M1/22.25 (1:500 dilution of tissue culture su-
pernatant in 5% BSA in PBS). After incubating for 1 h at room temperature, the
plate was rinsed three times in PBS, then overlaid with peroxidase-conjugated
goat anti-rat IgM antibodies (1:5,000 in 5% BSA–PBS), and incubated for a
further 30 min at room temperature. The plate was then washed seven times for
5 min each with 0.05% Tween 20 in PBS, then immersed for 1 min in ECL
reagent (NEN DuPont), and immediately exposed to Kodak XAR film.
For overlay with radiolabeled toxin, a crude lipid extract was prepared from
1.5  105 of each of the cell types, and the lipids were separated by TLC as
described above. After air drying the plates overnight, the edges were painted
with nail polish and the plates were blocked for 1 h in 5% BSA in PBS. Plates
were then incubated for 2 h at room temperature with 125I-labeled Stx1 prepared
as above (106 cpm diluted into 15 ml of 5% BSA in PBS). Thereafter, plates were
washed five times in PBS at room temperature over a 4-h period, covered with
Saran wrap, and exposed to film.
RESULTS
Cloning of the murine FS cDNA. FS modifies GbO4 to FG
by adding an N-acetylgalactosamine residue. Our investigators
previously described cloning and characterization of the canine
(9) and human (36) FS cDNAs. All human tissues were found
to express a message encoding full-length FS protein, yet the
protein lacked enzymatic activity (36). We demonstrate here
that mice also express a functional FS enzyme. Glycolipid
extraction and immuno-TLC overlay and RNase protection
assays demonstrated that FS is widely expressed in murine
tissues (data not shown). A portion of the murine FS cDNA
was amplified from mouse genomic DNA using oligonucleo-
tides derived from conserved regions within the human and
canine FS genes. Using this fragment of the murine FS as
probe, we demonstrated by Northern blot analysis that the FS
message was expressed at all stages of development and in all
adult tissues examined, with highest expression levels in the
lung (data not shown). In order to further elucidate the mo-
lecular evolution of the FS gene, we undertook cloning of the
murine FS cDNA. The transcriptional start site and start
codon were identified by 5-RACE. The same portion of the
murine FS was used as probe to screen a genomic library,
yielding one clone containing the entire coding region. Based
on the sequence obtained from the RACE product and
genomic locus, the entire coding region was amplified from a
murine lung cDNA library using flanking primers. The result-
ing cDNA was found to encode functional FS by transfecting
Vero cells and labeling with anti-FG antibodies (data not
shown). Sequence analysis demonstrated that overall, the mu-
rine, canine, and human FS proteins were 97% identical at the
amino acid level. Although highest homology was found be-
tween the canine and human FS proteins (Fig. 1), the canine
and murine enzymes demonstrated FS activity while the hu-
man gene product was devoid of FS activity (36).
Vero cells expressing a functional FS demonstrate reduced
susceptibility to Stx. Stx exerts its cytotoxic effect by enzymatic
inhibition of the ribosome, resulting in inhibition of protein
synthesis and, ultimately, cell death. In order to examine the
consequence of FS expression on Stx susceptibility, protein
synthesis inhibition assays were performed on Vero cells stably
transfected with the three FS homologues or a truncated, non-
functional version of the canine FS as a wild-type (FS-nega-
tive) control. Cells were exposed to various concentrations of
toxin, and the percent inhibition of protein synthesis was de-
termined relative to that in cells that did not receive toxin.
Whereas wild-type Vero cells or those expressing the human
FS were exquisitely susceptible to Stx (greater than 90% inhi-
bition at toxin concentrations as low as 10 pg/ml), those ex-
pressing the canine or murine FS cDNA demonstrated only
partial inhibition of protein synthesis, even at high toxin con-
centrations (Fig. 2). Similar results were obtained with human
bladder epithelial cells (T-24) transfected with the three FS
orthologues (data not shown).
Stx binding correlates inversely with the level of FG expres-
sion. Glycolipid expression levels are known to vary from cell
to cell among an asynchronously dividing population (20). We
therefore next examined the relationship between levels of FG
expression and Stx binding to individual cells. Dual labeling of
wild-type Vero cells and those stably transfected with the ca-
nine FS was performed with AlexaFluor 488-conjugated StxB
and anti-Forssman monoclonal antibody with an AlexaFluor
568-conjugated secondary antibody. Although FS-transfected
cells were selected in the presence of high concentrations of
neomycin (800 g/ml) and sorted for the presence of FG, we
found within three to four passages that a fraction of cells had
lost expression of FG, and this fraction increased with sequen-
tial passage. Successive selection of FG-positive cells by FACS
was unable to select for stably Forssman-reactive cells, nor was
isolation of individual FG-positive clones. In all cases, a por-
tion of selected cells became less Forssman reactive over time.
This heterogeneity in FG expression allowed us to examine the
relationship between FG expression and binding of Stx to
individual cells.
Wild-type cells did not react with anti-Forssman antibodies
and, as expected for cells dividing asynchronously (20), bound
varying amounts of toxin, as judged by confocal immunofluo-
rescence and FACS (Fig. 3). As demonstrated in the two con-
focal immunofluorescence images, wild-type cells bound vary-
ing amounts of StxB-Alexa 488 and did not bind anti-FG
antibodies, as evidenced by the lack of labeling with the Alexa
568-conjugated secondary antibody. These results are pre-
sented graphically after FACS analysis and plotting of StxB
binding along the x axis and anti-FG binding on the y axis.
Wild-type cells are found in the lower two quadrants, reflecting
varying amounts of StxB binding. As expected, very few cells
are shifted to the upper quadrants, reflecting the lack of an-
ti-FG reactivity. In contrast, within a population of cells ex-
pressing the canine FS, there was an inverse relationship be-
tween the presence of FG and Stx binding, as demonstrated
both by confocal immunofluorescence and FACS (Fig. 3). The
two immunofluorescence images demonstrate that binding of
StxB and anti-FG tend not to overlap. Cells that were strongly
bound by Stx did not express FG, and vice versa. Graphically,
this is evident in the FACS profile, where few cells are found
in the upper right quadrant (which would indicate binding of
both StxB and anti-FG). Instead, there is an inverse correlation
between FG expression and StxB reactivity, suggesting that
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increasing amounts of FG production result in a decreased
presence of Stx receptor glycolipids.
Stx exposure selects for high-level FG expression. Cells sta-
bly transfected with the FS cDNA were found to contain vary-
ing amounts of FG (Fig. 3). As described previously, in the
absence of toxin a tendency toward diminished FG quantity
with serial passage was found. We demonstrated above that
cells expressing the FS cDNA were heterogeneous in their
level of FG expression. Here, we examined the effect of Stx
exposure on expression of globoseries glycolipids among cells
capable of producing GbO3, GbO4, and FG. Notably, a Stx-
resistant Vero cell line was selected by serial passage in toxin,
and these cells were found to be deficient in GbO3 synthesis
(27). Therefore, in cells expressing FS, resistance to Stx may
result either from complete loss of GbO3 expression or by
high-level FS expression, with consequent depletion of GbO3
and GbO4 via synthesis of FG. We were therefore interested in
whether loss of GbO3 and globoseries glycolipid expression or
increased FG would occur in the population of FS-expressing
cells upon serial passage in Stx.
In the absence of toxin, a tendency toward diminished FG
quantity with serial passage was found. In contrast, cells cul-
tured in the presence of Stx demonstrated uniformly high-level
expression of FG over several months of passage (Fig. 4A).
These strongly Forssman-positive cells proliferated in toxin
concentrations as high as 100 ng of Stx/ml, greater than 10,000-
fold above the minimal concentration required to kill FS-neg-
ative cells. High-level FG expression correlated with minimal
Stx binding (Fig. 4A and 5A, below) but had no effect on
binding of cholera toxin B-subunit, which recognizes the un-
related glycolipid GM1 (10, 21) (Fig. 4B). Likewise, internal-
ization and trafficking of cholera toxin B-subunit to the Golgi
FIG. 1. Sequence comparison of FS orthologues. (A) The deduced peptide sequences of canine, murine, and human FS proteins are aligned.
Identical residues are shaded and boxed, while similar residues are lightly shaded. (B) Schematic representation of the relatedness of FS ortho-
logues. The canine, murine, and human FS peptide sequences were compared by using ClustalW, and the output was plotted by unrooted bootstrap
analysis.
6546 ELLIOTT ET AL. INFECT. IMMUN.
 o
n
 January 16, 2014 by W







was unaffected in Stx-selected cells, indicating that FS expres-
sion and toxin selection did not affect the retrograde trafficking
of another glycolipid-binding toxin (data not shown).
High-level FG expression correlates with markedly dimin-
ished GbO3 content. As described above, Stx exposure selected
for cells expressing high-levels of FG. In order to demonstrate
that the mechanism of Stx resistance was depletion of Stx
glycolipid receptors GbO3 and GbO4 via their conversion to FG,
we first performed Stx binding assays. Wild-type or FS-express-
ing cells were incubated in increasing concentrations of 125I-
labeled StxB in the presence or absence of excess competing
unlabeled toxin. While wild-type Vero cells demonstrated max-
imal binding (Bmax) of 790 fmol of toxin per 10
6 cells, FS-ex-
pressing cells selected in toxin had minimal toxin bound (Fig. 5A).
We next examined wild-type and FS-transfected, toxin-se-
lected cells for the presence of glycolipids GbO3 and FG. Total
lipids were extracted and separated by TLC. Glycolipids GbO3
and FG were immunologically detected by TLC overlay (9). As
expected, GbO3 but not FG was detected in wild-type cells. In
contrast, toxin-selected cells lacked detectable GbO3 and in-
stead demonstrated the presence of FG (Fig. 5B). These re-
sults indicate that expression of the FS cDNA is capable of
depleting cells of GbO3 via conversion to FG.
Finally, in order to compare binding of Stx to glycolipids of
wild-type and FS-transfected cells, total lipid extracts were
separated by TLC and the samples were overlaid with radio-
labeled Stx1. As expected, Stx1 bound to a band comigrating
with GbO3 in control and wild-type Vero cell extracts. Lesser
binding was seen to a band comigrating with GbO4. In contrast,
in FS cell extracts (cells transfected with the canine FS and
cultured in the presence of Stx), no binding was seen to GbO3,
whereas minimal binding to GbO4 was still detected (Fig. 5C).
These results are consistent with the markedly decreased GbO3
levels we demonstrated immunologically in Fig. 5B. Similarly,
these findings support the suggestion from whole-cell binding
assays that FS cells retain very little ability to bind Stx.
DISCUSSION
A crucial first step in the pathogenesis of bacterial and viral
infections is adherence of the organism to host cell surfaces
(2). In general, microbial adherence demonstrates high speci-
ficity for receptors expressed in a species- and tissue-specific
manner on the eucaryotic cell surface. As a consequence, mi-
crobes usually demonstrate the propensity to bind a limited
repertoire of tissues and hosts. Over the last several years it has
become evident that this tropism is often a consequence of
specific microbial adherence to carbohydrate structures pres-
ent on glycoproteins or, more commonly, on glycolipids.
We describe here a relationship between FG synthesis and
FIG. 2. Vero cells expressing a functional FS are resistant to Stx. Cells stably transfected with the human, truncated canine (wild-type), murine,
or canine FS were incubated with various concentrations of Stx and pulsed with [35S]methionine, and the amount of incorporated radiolabel was
determined by TCA precipitation and scintillation counting. Data represent the mean of triplicate samples.
VOL. 71, 2003 FORSSMAN SYNTHETASE EXPRESSION AND Stx SUSCEPTIBILITY 6547
 o
n
 January 16, 2014 by W







FIG. 3. Stx binding correlates inversely with FG expression. Wild-type Vero cells or those stably transfected with the canine FS were dual
labeled with AlexaFluor 488 StxB (green) or anti-Forssman antibodies and AlexaFluor 568 (red)-conjugated secondary antibody. Labeled cells
were visualized by confocal immunofluoroscopy and FACS. For each cell type, two immunofluorescence panels are shown above the FACS profile
of the same cells. The FACS data are presented with Stx1 reactivity plotted on the x axis and anti-FG reactivity on the y axis. Binding of both StxB
and anti-FG would shift cells to the upper right quadrant, whereas a shift to the upper left or lower right quadrants indicates binding of only anti-
FG or StxB, respectively.
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Stx susceptibility. Primate cells, normally exquisitely suscepti-
ble to Stx, demonstrated markedly reduced susceptibility upon
expression of the FS cDNA. Exposure of a heterogeneous
population of cells expressing FS to Stx was found to select for
those cells expressing high levels of FG. At the molecular level,
these cells were found to lack the ability to bind Stx due to a
markedly reduced content of Stx receptor glycolipids. Thus,
expression of FS results in diminished susceptibility to Stx by
converting toxin receptor glycolipids GbO3 and GbO4 to re-
ceptor-inactive FG. We believe that these in vitro conditions
mimic an important interplay that occurs in nature between
host glycolipid expression and microbial pathogenesis. These
results demonstrate that intraspecies differences in glycolipid
expression can have marked effects on the susceptibility to an
infectious agent. Moreover, these findings provide insight into
the molecular evolution of glycosyltransferase gene expression.
Glycolipids consist of a carbohydrate moiety attached to
a ceramide backbone. Classification of glycolipids is usually
based upon their carbohydrate structure, which varies in length
from one sugar residue to six and occasionally more. Variabil-
ity arises in the oligosaccharide structures through differences
in the type of sugar residues incorporated and in the anomeric
linkage between sugar residues ( versus 	, 1-3 versus 1-4,
etc.). Thus, glycolipids may contain a great number of distinct
carbohydrate moieties. Each cell type, however, expresses gly-
colipids that contain a limited repertoire of all possible carbo-
hydrate structures. In mesenchymal tissues of mammalian spe-
cies, the globoseries glycolipids (those having GbO3 as a core)
are the predominant members. As demonstrated herein, mod-
ification of globoseries glycolipids to extended forms, such as
FG, results in diminished susceptibility to Stx. Aside from
apparent differences in susceptibility to infectious agents, the
relative costs and benefits of varied glycolipid expression be-
tween species is unknown.
FIG. 5. Cells expressing high levels of FG fail to bind Stx due to decreased GbO3 content. (A) Wild-type Vero cells or those transfected with
the canine FS and passaged in Stx were incubated with various concentrations of 125I-labeled StxB (total) or excess unlabeled toxin (nonspecific).
After washing, the amount of bound [125I]StxB was quantitated. Data represent the mean of duplicate samples. (B) Crude lipid extracts were
prepared from wild-type Vero cells (WT) or FS-transfected cells exposed to Stx (FS). After separation by TLC, GbO3 or FG was detected by
monoclonal antibody followed by peroxidase-conjugated secondary antibody and ECL. (C) Glycolipids were extracted from 2  105 untransfected
(“C”) Vero cells or those transfected with the human FS (WT) or canine FS exposed to Stx (FS). After separation by TLC, extracts were overlaid
with 125I-labeled Stx1. After washing, bound toxin was detected by autoradiography. Migration of glycolipids standards is indicated by the arrows.
CDH, ceramide dihexoside.
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There is considerable evidence that glycolipids play impor-
tant roles in normal cellular biology (1), yet their precise func-
tion remains unknown. In many cases it appears that glycolipid
function is flexible, given the high degree of variability in gly-
colipid synthesis among species (7, 34). Like other glycolipids,
FG has been proposed to play important roles in cellular bi-
ology. FG is expressed in a tissue-specific and developmentally
regulated fashion in such diverse mammals as dog, sheep,
horse, guinea pig, and mouse. The absence of FG in normal
human tissues indicates either that this molecule is dispensable
or that the function of FG has been subsumed by another
glycolipid during primate evolution. FS expression appears to
share many features with the closely related 1,3-galactosyl-
transferase gene. Like FS, the 1,3-galactosyltransferase gene
is conserved among mammalian species, including humans.
However, at some point in primate evolution, mutations in the
gene rendered the 1,3-galactosyltransferase nonfunctional.
Joziasse et al. estimate that the 1,3-galactosyltransferase gene
became nonfunctional between 40 and 25 million years ago,
based on the observation that Old World monkeys and humans
lack functional enzyme while New World primates are capable
of synthesizing the 1,3-galactose structure (13, 14). One con-
sequence of the lack of 1,3-galactose synthesis among hu-
mans is the natural production of antibodies against the 1,3-
galactose linkage. These antibodies have been proposed to be
a barrier to infection by enveloped viruses derived from ani-
mals that express the 1,3-galactose linkage (31). Thus, loss of
1,3-galactosyltransferase expression may protect humans
from infections that are common in other species. Like the
human FS gene, the nonfunctional 1,3-galactosyltransferase
message was found to be expressed, albeit at low levels, in
some human tissues (16). Given the near identity of the human
FS with functional canine and murine orthologues, and in
analogy to molecular evolution of the related 1,3-galactosyl-
transferase gene, we propose that the ability to synthesize FG
was lost recently in primate evolution.
In mammalian populations, expression of various glycolipid
glycosyltransferases ranges from high level to absent between
species and even among individuals within a species (e.g., vari-
able histo-blood group antigen expression among humans) (5).
A common theme emerging from studies on the molecular
evolution of glycosyltransferase expression suggests that selec-
tion by infectious microbes or toxins may have had a major
influence on the evolution of glycoprotein and glycolipid ex-
pression (7, 11, 34). This hypothesis predicts that interaction
with infectious agents throughout mammalian evolution may
have selected for or against expression of individual glycolipids
(7, 16). In the case of FG expression, colonization with toxi-
genic bacteria may provide selective pressure for maintaining
FS expression. Alternatively, modification of GbO3 to other
extended-chain glycolipids would be expected to have a similar
effect of depleting cells of toxin receptors and to correlate with
diminished Stx susceptibility. However, human endothelial
cells fail to produce such extended globoseries glycolipids and
are unable to synthesize FG, contributing to high levels of
GbO3 expression and their marked Stx susceptibility.
Microbes and bacterial toxins typically cause disease in a
limited number of host species. A major determinant of such a
tropism is the ability of a pathogenic organism or toxin to bind
to host cells (2, 8, 12). As is the case with Stx binding, glyco-
lipids are highly represented among cell surface receptors for
microbial adhesins and bacterial toxins. Variability in glyco-
lipid expression is expected to affect the tropism for various
microbes and toxins for host tissues (6, 11, 15, 18, 29). Expres-
sion of a functionally inactive FS in all human tissues suggests
that loss of FG synthesis occurred recently in human evolution.
The results presented here demonstrate that, were it functional,
the human FS would provide a degree of resistance to Stx.
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